Ludwig Maximilian University Hospital, Munich – Germany
About Prof. Dr. Med. Michael Von Bergwelt
Prof. Dr. Med. Michael Von Bergwelt is a globally recognised Medical Oncologist with over 28 years of experience in haematology, oncology, bone marrow transplantation, and cancer immunotherapy, and is regarded as one of the leading Medical Oncologist specialists in Munich, Germany. His pioneering work in CAR-T cell therapy and immune checkpoint inhibition has shaped modern precision oncology in Europe.
- 28+ years of experience in internal medicine, haematology & medical oncology
- 594+ scientific publications with 17,000+ academic citations
- Consistently ranked among Germany’s Top 100 Oncologists by FOCUS magazine
- Recipient of the prestigious Mildred-Scheel Fellowship (German Cancer Aid)
- Chairman of the German Consortium for Translational Cancer Research (DKTK), since 2020
- Pioneer in CAR-T cell therapy & checkpoint inhibitors for lymphoma and melanoma
Qualifications & Credentials
Medical Degrees
- Medical Studies — Universities of Münster, Freiburg & Paris (Paris-South XI), 1988–1996
- MSc in Biological & Medical Sciences (Human Biology) — Université Paris-Sud XI, France
- MD (Dissertation) — University of Freiburg, Germany, 1997 — Thesis on tumour-infiltrating lymphocytes in colorectal carcinoma
Fellowships & Special Training
- Mildred-Scheel Fellowship — German Cancer Aid (Deutsche Krebshilfe)
- Board Certification in Internal Medicine, Haematology & Medical Oncology, Germany
- Board Certification in Emergency Medicine, Lower Saxony, 1999
- Specialised training in Bone Marrow Transplantation & Cellular Immunotherapy
Certifications & Accreditations
- German Medical Council (Ärztekammer) Registration
- Professor — Department of Oncology, University Hospital LMU Munich (since 2017)
- Member — German Cancer Consortium (DKTK)
- Member — European Society for Blood and Marrow Transplantation (EBMT)
Areas of Expertise
Major Conditions Treated
- Acute & Chronic Leukaemia
- Hodgkin & Non-Hodgkin Lymphoma
- Multiple Myeloma
- Bone & Soft Tissue Sarcomas
- Gastrointestinal Cancers (Stomach, Colon, Pancreatic, Liver)
- Lung Cancer & Mesothelioma
- Breast Cancer
- Head & Neck Cancers
- Neuroendocrine Tumours
- Cancer of Unknown Primary (CUP)
- Malignant Ascites
Sub-specialties
- Cellular Cancer Immunotherapy & CAR-T Therapy: Pioneer in CD19 CAR-T cell therapy for large B-cell lymphoma — a leading medical oncologist in Munich, Germany for cellular immunotherapy.
- Bone Marrow & Stem Cell Transplantation: Allogeneic and autologous transplant for leukaemia, lymphoma, and myeloma.
- Precision & Molecular Oncology: Molecular tumour board–led personalised treatment for rare and complex cancers — sought by international patients researching the best medical oncologist in Germany.
Advanced Procedures & Treatments
- CAR-T Cell Therapy (CD19, BCMA)
- Allogeneic & Autologous Stem Cell Transplantation
- Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)
- Bispecific T-cell Engagers (e.g., Blinatumomab)
- Targeted Therapy & Molecular Profiling
- Hyperthermia combined with Chemotherapy (for sarcomas)
- Antibody Therapy
- High-Dose Chemotherapy with Stem Cell Rescue
List of Disease and Treatment for which Prof. Dr. Med. Michael Von Bergwelt can be consulted
Professional Experience
Current Affiliation
- University Hospital Ludwig-Maximilians-Universität (LMU), Munich, Germany — Director, Medical Clinic and Polyclinic III; Professor & Chair, Department of Medicine III (Haematology, Oncology, Bone Marrow Transplantation) — 2017–Present
Past Affiliations
- University Hospital Cologne, Germany — Senior Consultant & Researcher, Haematology / Oncology (Past)
- University of Freiburg, Germany — Postgraduate clinical & research training (Past)
Academic & Research Roles
- Professor & Chair — Internal Medicine with focus on Haematology & Medical Oncology, LMU Munich
- Chairman — German Consortium for Translational Cancer Research (DKTK), since 2020
- Founding member — iCHOP and Nine-I (intensive care for haematology/oncology patients)
- Co-founder — Tabby Therapeutics & Vision Zero (cellular cancer immunotherapy initiatives)
Key Achievements
- 594+ peer-reviewed scientific publications
- 17,000+ citations in international research literature
- Consistently ranked in FOCUS Top 100 Oncologists in Germany
- 9.80/10 expert rating on AiroMedical international medical platform
- Leadership of major translational cancer research consortia in Germany
Awards & Recognitions
National & International Awards
- Mildred-Scheel Fellowship — German Cancer Aid (Deutsche Krebshilfe)
- Basic Science Award — European Society for Blood and Marrow Transplantation (EBMT), 2010
- Travel Award — American Society of Hematology (ASH)
- FOCUS Top 100 Oncologists in Germany (recurring)
Professional Memberships
- German Cancer Consortium (DKTK)
- European Society for Blood and Marrow Transplantation (EBMT)
- Lymphoma Research Foundation of America
- German José Carreras Leukaemia Foundation
- American Society of Hematology (ASH)
Research & Publications
Published Papers (Selected)
- von Bergwelt-Baildon M, et al. Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma. (Co-authored multi-centre study).
- Auernhammer C J, von Bergwelt-Baildon M, et al. Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCC Munich LMU Molecular Tumor Board.
- von Bergwelt-Baildon M, et al. Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups.
- von Bergwelt-Baildon M, et al. Phenotypical and functional characterization of tumor-infiltrating lymphocytes in colorectal carcinoma under stimulation with Interleukin-2 and Interleukin-4 in vitro. MD Dissertation, University of Freiburg, 1997.
- 594+ additional peer-reviewed publications across haematology, oncology, and immunotherapy.
Ongoing Research & Clinical Interests
- B cells in cancer biology & immunotherapy
- CAR-T cell therapy in solid tumours and lymphoma
- Immune checkpoint inhibition in Hodgkin lymphoma
- Precision oncology & molecular tumour boards
- Bispecific T-cell engagers (e.g., blinatumomab) in autoimmune-related haematology
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Medical Oncology Consultation | ₹15,000 – ₹30,000 | $180 – $360 |
| Chemotherapy (per cycle, regimen-dependent) | ₹1,00,000 – ₹5,00,000 | $1,200 – $6,000 |
| Immunotherapy / Checkpoint Inhibitor (per cycle) | ₹2,50,000 – ₹6,00,000 | $3,000 – $7,200 |
| CAR-T Cell Therapy (per treatment) | ₹2,00,00,000 – ₹3,50,00,000 | $240,000 – $420,000 |
| Allogeneic Stem Cell Transplant | ₹65,00,000 – ₹1,50,00,000 | $78,000 – $180,000 |
| Molecular Tumour Profiling | ₹2,50,000 – ₹6,00,000 | $3,000 – $7,200 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Prof. Dr. Med. Michael Von Bergwelt use in Medical Oncologist treatment?
Prof. Dr. Med. Michael Von Bergwelt employs cutting-edge oncology technologies including CAR-T cell therapy, immune checkpoint inhibitors (PD-1/PD-L1), bispecific T-cell engagers, allogeneic and autologous stem cell transplantation, hyperthermia-enhanced chemotherapy, and molecular tumour profiling. International patients can request virtual second opinions through Cancer Rounds.
2. What conditions does Prof. Dr. Med. Michael Von Bergwelt specialize in treating?
As a leading medical oncologist specialist in Munich, Germany, Prof. Von Bergwelt treats acute & chronic leukaemia, Hodgkin & non-Hodgkin lymphoma, multiple myeloma, sarcomas, lung cancer, breast cancer, gastrointestinal cancers, mesothelioma, head & neck cancers, and rare cancers like neuroendocrine tumours and CUP — making him one of the best medical oncologist doctors in Germany for complex and refractory cancers.
3. How do I book an appointment with Prof. Dr. Med. Michael Von Bergwelt?
Appointments with Prof. Dr. Med. Michael Von Bergwelt can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Prof. Dr. Med. Michael Von Bergwelt?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Prof. Dr. Med. Michael Von Bergwelt, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Prof. Dr. Med. Michael Von Bergwelt offer second opinions for Medical Oncologist cases?
Yes. Second opinion consultations with Prof. Dr. Med. Michael Von Bergwelt can be arranged via Cancer Rounds for patients seeking expert review of cancer treatment plans, CAR-T eligibility, or transplant options from a Medical Oncologist specialist in Munich, Germany.
University Hospital Rechts der Isar - Germany
Blood Cancer
